Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238220 · ClinicalTrials.gov registry record
Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
A clinical trial, sponsored by Piedmont Healthcare.
- Completed
- Registry status
- 37
- Enrollment target
NCT05238220: Completed study, sponsored by Piedmont Healthcare.
NCT05238220 is a clinical trial that has completed, run by Piedmont Healthcare. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05238220 has completed, sponsored by Piedmont Healthcare.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients at higher risk of post-prophylaxis CMV viremia or disease and thereby select those patients in which a longer duration of valganciclovir prophylaxis would be beneficial.
Primary Outcome
continue valganciclovir prophylaxis for additional time due to absence of demonstrated anti-CMV immunity
Interventions
- DRUG Valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2022-06-30 |
What the finished NCT05238220 record still lists
NCT05238220 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Valganciclovir is the first listed.
NCT05238220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05238220 about?
NCT05238220 is a clinical study titled "Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients". The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients at higher risk of post-prophylaxis CMV viremia or disease and thereby select those patients in whic...
What is the current status of trial NCT05238220?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2021-01-04. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT05238220?
The interventions under investigation include: Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT05238220?
This trial is sponsored by Piedmont Healthcare, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI